On January 8, 2026, Climb Bio, Inc. shared progress on its clinical trials, including dosing the first patient in a Phase 2 trial for primary membranous nephropathy and milestones for 2026. The company expects its funds to last into 2028 and plans to release initial trial data throughout 2026.